Welcome to our dedicated page for Coherus SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology, Inc. filed an 8-K reporting a change in its independent auditor. On June 12, 2026, the Audit Committee dismissed Ernst & Young LLP as the company’s independent registered public accounting firm. EY’s audit reports on the 2024 and 2025 financial statements contained no adverse opinions, disclaimers, or qualifications, and the company reports no disagreements or reportable events with EY, other than a previously disclosed material weakness in internal control over certain inventory reconciliations that has since been remediated.
On the same date, the Audit Committee selected PricewaterhouseCoopers LLP to serve as independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures. EY has been asked to provide, and has provided, a letter to the SEC agreeing with the company’s disclosures, which is included as Exhibit 16.1.
Coherus Oncology director Ali J. Satvat received new equity awards. On June 5, 2026, he was granted 30,000 restricted stock units, each convertible into one share of common stock upon vesting. According to the terms, all RSUs vest 100% on the one-year anniversary of June 3, 2026, subject to his continued service.
He also received a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share. This option vests and becomes fully exercisable on June 3, 2027, conditional on his continued service with the company, and expires on June 5, 2036.
Coherus Oncology, Inc. reported that director Rita A. Karachun received equity compensation on June 5, 2026. She was granted 30,000 restricted stock units (RSUs), each convertible into one share of common stock upon vesting, with 100% of the RSUs vesting on the one year anniversary of June 3, 2026, subject to her continued service. She was also granted a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share, which vests and becomes exercisable in full on June 3, 2027, subject to continued service. Following these awards, she holds 30,000 shares of common stock and 60,000 stock options directly.
Coherus Oncology, Inc. director Newcomer Lee Nisley reported compensation-related equity grants. The reporting person received 30,000 shares of Common Stock, which footnotes describe as restricted stock units (RSUs) that convert into one share of common stock per unit upon vesting. All 30,000 RSUs vest on the one-year anniversary of June 3, 2026, contingent on continued service. In addition, the reporting person was granted 60,000 stock options with an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable for all 60,000 underlying shares of Common Stock on June 3, 2027, also subject to continued service with the company.
Coherus Oncology, Inc. director Ryan Michael Lee reported receiving new equity-based compensation. He was granted 30,000 restricted stock units (RSUs), each representing one share of common stock upon vesting, and now holds 30,000 common shares directly after this award.
According to the filing, 100% of these RSUs will vest on the one-year anniversary of June 3, 2026, assuming he continues his service with the company. Lee also received stock options for 60,000 shares of common stock at an exercise price of $1.45 per share, which vest and become exercisable in full on June 3, 2027, subject to continued service.
Coherus Oncology, Inc. director Jill O'Donnell-Tormey reported equity awards in the form of common stock and stock options. She received 30,000 shares of Common Stock as restricted stock units, at no purchase price, with 30,000 shares held directly after this grant.
She was also granted stock options for 60,000 shares of Common Stock with an exercise price of $1.45 per share, expiring on June 5, 2036. According to the footnotes, the 30,000 RSUs vest in full on the one year anniversary of June 3, 2026, and the 60,000 options vest and become exercisable in full on June 3, 2027, in each case subject to her continued service with the company.
Coherus Oncology, Inc. director Mats Wahlstrom reported equity awards consisting of common stock and stock options as compensation. He received 30,000 shares of Common Stock that constitute restricted stock units, each converting into one share upon vesting. These RSUs vest 100% on the one-year anniversary of June 3, 2026, contingent on his continued service. He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, vesting in full on June 3, 2027, also subject to continued service, and expiring on June 5, 2036. Following these awards, Wahlstrom holds 30,000 shares of Common Stock directly and 60,000 stock options.
Coherus Oncology director Charles W. Newton reported equity compensation grants. He received 30,000 shares of Common Stock in the form of restricted stock units, with one share delivered for each unit upon vesting. The RSUs vest 100% on the one year anniversary of June 3, 2026, contingent on his continued service.
He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable in full on June 3, 2027, also subject to his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 options directly.
Coherus Oncology Chief Financial Officer granted repriced options
Coherus Oncology, Inc. reported that its Chief Financial Officer, Bryan J. McMichael, received several grants of stock options on May 29, 2026, each with an exercise price of $1.59 per share and expirations on May 29, 2036. These options cover multiple blocks, including grants for 100,000, 30,000, 25,000, 25,000, 25,000, and 15,000 shares of common stock as compensation.
On the same date, the company recorded dispositions of earlier stock options back to the issuer, in matching share amounts but with higher exercise prices ranging from $5.44 to $14.76 per share, reflecting a stockholder-approved option repricing for options previously priced at or above $5. No open‑market purchases or sales of common stock were reported in this filing.
Coherus Oncology, Inc. reported that President & CEO Dennis M. Lanfear received multiple stock option grants covering a total of 3,205,000 shares of common stock at an exercise price of $1.59 per share. These new options replace an equal number of older options with exercise prices ranging from $5.44 to $18.33, which were disposed of back to the company.
Stockholders approved this option repricing on May 29, 2026, and the repricing is conditioned on Lanfear remaining in service through May 29, 2027. One block of options vests in 1/48th monthly installments measured from January 5, 2023, while another block is fully vested and exercisable, aligning his compensation structure more closely with the current share price.